About Cerexa
Cerexa is a Healthcare company based in Alameda (United States) founded in 2005, and was acquired by Forest Laboratories in December 2006. Hospital-based anti-infective therapies for antibiotic-resistant infections are developed. The company has 2,961 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is AbbVie Deutschland GmbH & Co. KG. Its competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Cerexa is focused on the development of hospital-based anti-infective therapies to infections that are resistant to antibiotics. Its product portfolio includes Ceftaroline Acetate, a hospital-based cephalosporin antibiotic that exhibits bactericidal activity against the strains of Gram- positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus); ME1036, a broad-spectrum parenteral carbapenem against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including common drug-resistant pathogens. On December 13, 2006 Forest Laboratories acquired Cerexa for a total of 480M.
- Headquarters Alameda, United States
- Employees 2,961
- Stage Acquired
- SectorsHealthcare
- Website cerexa.com
- Social LinkedIn
- Acquired by Forest Laboratories (Dec 2006)
- Legal Name Abbvie Deutschland Gmbh & Co. Kg
- Investors
- Employee Count2,961
- Acquired byForest Laboratories
(Dec 2006)
Investors in Cerexa
Cerexa has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Forest Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical formulations are developed and marketed by Forest Laboratories. | 1954 | frx.com | New York, United States |
Investor details for Cerexa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cerexa
2 dated milestones of Cerexa across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Cerexa is founded.
- Exit Acquired by Forest Laboratories.
Competitors of Cerexa
Cerexa has 3 listed competitors in our database, 3 of them funded. They include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. |
Detailed competitors of Cerexa
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cerexa
Websites that share an audience with Cerexa (cerexa.com).
Websites whose visitors overlap most with Cerexa. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Infectious Diseases
3 companies that operate in the same segment as Cerexa (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cerexa
Cerexa was founded in 2005.
Cerexa is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Cerexa has 2,961 employees.
Cerexa is focused on the development of hospital-based anti-infective therapies to infections that are resistant to antibiotics. Its product portfolio includes Ceftaroline Acetate, a hospital-based cephalosporin antibiotic that exhibits bactericidal activity against the strains of Gram- positive bacteria, including MRSA (methicillin-resistant Staphylococcus aureus); ME1036, a broad-spectrum parenteral carbapenem against both aerobic and anaerobic Gram-positive and Gram-negative bacteria, including common drug-resistant pathogens. On December 13, 2006 Forest Laboratories acquired Cerexa for a total of 480M.
Cerexa's top competitors include Spero Therapeutics, Melinta Therapeutics and Adaptive Phage Therapeutics.
Cerexa has 1 investor. Key investors include Forest Laboratories.
Cerexa operates through Abbvie Deutschland Gmbh & Co. Kg.
Yes. Cerexa was acquired by Forest Laboratories in December 2006.